Drug Profile
Research programme: serine protease inhibitor therapeutics - SERPINx
Alternative Names: modified variants of α1-antitrypsins; SERPIN1; SPx 001Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator SERPINx
- Class Anti-inflammatories; Antithrombotics; Kinins; Peptide hydrolases; Peptides; Proteins; Vascular disorder therapies
- Mechanism of Action Serine protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hereditary angioedema; Inflammation; Thrombosis
- No development reported Angioedema
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Angioedema in Netherlands
- 24 Sep 2020 Preclinical trials in Hereditary angioedema in Netherlands (unspecified route) before September 2020 (SERPINx pipeline, September 2020)
- 24 Sep 2020 Preclinical trials in Inflammation in Netherlands (unspecified route) before September 2020 (SERPINx pipeline, September 2020)